trial summary · NCT07892027
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Phase II Trial of Natalizumab for Prevention of Immune Effector Cell Associated Neurologic Syndrome (ICANS) in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy for B-Cell Hematologic Malignancies
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Diffuse Large B-Cell Lymphoma, sponsored by University of Michigan Rogel Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) receiving chimeric antigen receptor (CAR) T-cell therapy. A major complication of CAR T-cell therapy is ICANS. ICANS is inflammation of the brain or nerves. ICANS currently requires high-dose corticosteroid treatment which can inhibit CAR T-cell response. Natalizumab prevents immune cells from traveling from the blood to the fluid around the brain, which is a process thought to play a major role in CAR T-cell related brain injury. Natalizumab may be safe and effective in decreasing the frequency of severe ICANS in patients with DLBCL or MCL receiving CAR T-cell therapy.
Source record: https://clinicaltrials.gov/study/NCT07892027
Facts
| registry id | NCT07892027 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Diffuse Large B-Cell Lymphoma |
| sponsor | University of Michigan Rogel Cancer Center |
| sponsor class | OTHER |
| enrollment | 26 |
| start date | 2026-11-01 |
| primary completion | 2028-05-01 |
| completion | 2028-05-01 |
| results posted | not reported |
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
- Axicabtagene Ciloleucel
- Biospecimen Collection
- Brexucabtagene Autoleucel
- Computed Tomography
- Cyclophosphamide
- Fludarabine
- Natalizumab
- Positron Emission Tomography
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.